Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 105 posts found.

regeneron

Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths

November 3, 2020
Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma

Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …

News
libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

News
regeneron

Regeneron seals $450m BARDA contract to scale up production of its COVID-19 vaccine

July 9, 2020
Manufacturing and Production, Sales and Marketing BARDA, Operation Warp Speed, Regeneron, US, vaccine COVID-19

Regeneron has revealed that REGN-COV2, its two-antibody vaccine for the treatment and prevention of COVID-19, has been awarded a manufacturing …

News
shutter

Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer

May 5, 2020
Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …

News
shutterstock

Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer

April 29, 2020
Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer

A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …

News
nice_new_london_office_internal_3_web

NICE shoots down Dupixent for severe asthma

March 9, 2020
Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …

News

Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration

February 18, 2020
Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma

The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …

News
libtayo

Sanofi and Regeneron’s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma

February 11, 2020
Manufacturing and Production, Sales and Marketing Libtayo, NHS, Regeneron, Sanofi, Scotland, nhs scotland, pharma

Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known …

News
novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

News
ipos0_l

Regeneron invest $800 million into New York facilities

August 15, 2019
Medical Communications East Greenbush, New York, Regeneron, pharma

Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …

News
regeneron

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

August 15, 2019
Research and Development Regeneron, evinacumab, pharma, rare disease

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …

News
shutterstock_158366573

Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma

July 2, 2019
Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma

The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …

News
ipos0_l

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

May 14, 2019
Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …

News
heart-2372134_640

Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …

News
dupixentpackage

FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients

March 12, 2019
Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma

Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025